BioWorld

Feb. 18, 2005

Dendreon Shows Survival Benefit In Phase III Study Of Provenge

A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today) Read More

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

'Matchmaker' SNP Study Paves Way For Pharmacogenomics

BioCryst Raises $23.9M Privately To Fund Lead Clinical Products

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...

Chengdu Mfs Pharma synthesizes new compounds for pain

BioWorld Science

Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...